NASDAQ: GALT - Galectin Therapeutics Inc.

Lønnsomhet i seks måneder: -37.2%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Galectin Therapeutics Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

flere detaljer
The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2002-09-09
ISIN US3632252025
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://galectintherapeutics.com
Цена ао 1.52
Prisendring per dag: +6.08% (1.48)
Prisendring per uke: +5.37% (1.49)
Prisendring per måned: +27.64% (1.23)
Prisendring over 3 måneder: -45.67% (2.89)
Prisendring over seks måneder: -37.2% (2.5)
Prisendring per år: -18.65% (1.93)
Prisendring over 3 år: -20.71% (1.98)
Prisendring over 5 år: -40.3% (2.63)
Prisendring over 10 år: 0% (1.57)
Prisendring siden begynnelsen av året: +86.77% (0.8406)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV -1.77 0
P/E 0 0
EV/EBITDA -4.01 0
Total: 2.5

Effektivitet

Navn Betydning Karakter
ROA, % -145.62 0
ROE, % 68.17 10
Total: 3.33

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -1.89 10
Total: 9

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % -98.47 0
Lønnsomhet EPS, % 166.44 10
Total: 6
Flere detaljer

Institusjoner Volum Dele, %
Vanguard Group Inc 1941854 3.14
Osaic Holdings Inc 1251048 2.02
Blackrock Inc. 715351 1.16
Geode Capital Management, LLC 514416 0.83
Geneos Wealth Management, Inc. 412650 0.67
Atria Wealth Solutions, Inc. 249800 0.4
Morgan Stanley 185147 0.3
Wealthspire Advisors, LLC 183862 0.3
State Street Corporation 161440 0.26
Cambridge Investment Research Advisors Inc. 126581 0.2

ETF Dele, % Lønnsomhet for året, % Utbytte, %
iShares Micro-Cap ETF 0.01442 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00247 38.04 0.6026
ProShares UltraPro Russell2000 0.00122 89.82 1.47873
ProShares Hedge Replication ETF 0.00034 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264



Veileder Stillingstittel Betaling Fødselsår
Mr. Joel Lewis President, CEO & Director 907.72k 1970 (55 år)
Mr. Jack W. Callicutt CPA CFO, Treasurer & Corporate Secretary 521.47k 1967 (58 år)
Robert Tritt General Counsel N/A
Mr. Jeff Katstra Head of CMC & Pharmaceutical Development N/A
Ms. Beth Knowles Executive Assistant & Officer Manager N/A
Mr. Khurram Jamil M.D. Chief Medical Officer

Adresse: United States, Norcross. GA, 4960 Peachtree Industrial Boulevard - åpne i Google maps, åpne Yandex-kart
Nettsted: https://galectintherapeutics.com